Literature DB >> 2902690

Limited immunological recognition of critical malaria vaccine candidate antigens.

M F Good1, L H Miller, S Kumar, I A Quakyi, D Keister, J H Adams, B Moss, J A Berzofsky, R Carter.   

Abstract

Current vaccine development strategies for malaria depend on widespread immunological responsiveness to candidate antigens such as the zygote surface antigens and the sporozoite coat protein, the circumsporozoite (CS) protein. Since immunological responsiveness is controlled mainly by genes mapping within the major histocompatibility complex (MHC), the humoral immune response to the zygote surface antigens and the cytotoxic T lymphocyte (CTL) response to the CS protein were examined in MHC-disparate congenic mouse strains. Only two of six strains responded to the 230-kilodalton zygote surface antigen and another two strains responded to the 48/45-kilodalton surface antigen. From two mouse strains, expressing between them five different class I MHC molecules, there was recognition of only a single CTL epitope from the CS protein, which was from a polymorphic segment of the molecule. The restricted CTL response to this protein parallels the restricted antibody response to this protein observed in humans and mice. These findings suggest that subunit malaria vaccines now being developed may be ineffective.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2902690     DOI: 10.1126/science.2902690

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  19 in total

1.  Development of natural immunity in Plasmodium falciparum malaria: study of antibody response by Western immunoblotting.

Authors:  J Thelu; I Sheick-Zakiuddin; C Boudin; F Peyron; S Picot; P Ambroise-Thomas
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

Review 2.  Where are we in the quest for vaccines for malaria?

Authors:  W A Siddiqui
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

3.  Evidence implicating MHC genes in the immunological nonresponsiveness to the Plasmodium falciparum CS protein.

Authors:  M F Good; S Kumar; A S De Groot; W R Weiss; I A Quakyi; F Dontfraid; G E Smith; M Cochran; J A Berzofsky; L H Miller
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

4.  Segregation analysis detects a major gene controlling blood infection levels in human malaria.

Authors:  L Abel; M Cot; L Mulder; P Carnevale; J Feingold
Journal:  Am J Hum Genet       Date:  1992-06       Impact factor: 11.025

Review 5.  Status of malaria vaccine research.

Authors:  G A Targett
Journal:  J R Soc Med       Date:  1989       Impact factor: 5.344

6.  Localization of CS and non-CS antigens in the sporogonic stages of Plasmodium yoelii.

Authors:  M Aikawa; C T Atkinson; L M Beaudoin; M Sedegah; Y Charoenvit; R Beaudoin
Journal:  Bull World Health Organ       Date:  1990       Impact factor: 9.408

7.  Biochemical characterization, localization and immunostimulating properties of a soluble glycoprotein, Ag1, isolated from in vitro cultures of Plasmodium falciparum.

Authors:  P H Jakobsen; S Jepsen; E M Riley; T G Theander; P Grellier; A Lihme; L Hviid; M Dziegiel; J Schrevel
Journal:  Parasitol Res       Date:  1990       Impact factor: 2.289

8.  Generalized immunological recognition of the major merozoite surface antigen (gp195) of Plasmodium falciparum.

Authors:  S P Chang; G S Hui; A Kato; W A Siddiqui
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

9.  Distinct H-2 complex control of mortality, and immune responses to tuberculosis infection in virgin and BCG-vaccinated mice.

Authors:  A S Apt; V G Avdienko; B V Nikonenko; I B Kramnik; A M Moroz; E Skamene
Journal:  Clin Exp Immunol       Date:  1993-11       Impact factor: 4.330

10.  Plasmodium falciparum-specific cellular immune responses after immunization with the RTS,S/AS02D candidate malaria vaccine in infants living in an area of high endemicity in Mozambique.

Authors:  Arnoldo Barbosa; Denise Naniche; John J Aponte; M Nelia Manaca; Inacio Mandomando; Pedro Aide; Jahit Sacarlal; Montse Renom; Sarah Lafuente; W Ripley Ballou; Pedro L Alonso
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.